Monitoring
Symptoms should be reviewed every 3 to 6 months in order to evaluate the frequency and severity of attacks effectively. Careful consideration of the benefits and/or adverse effects of any pharmaceutical intervention should also be undertaken at each clinical review.
Use of this content is subject to our disclaimer